• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Mesenchymal Stem Cell-derived Neural Progenitor Cells in Progressive Multiple Sclerosis: Great Expectations.

作者信息

Baldassari Laura E, Cohen Jeffrey A

机构信息

Mellen Center for Multiple Sclerosis Research and Treatment, Neurological Institute, Cleveland Clinic.

Mellen Center for Multiple Sclerosis Research and Treatment, Neurological Institute, Cleveland Clinic.

出版信息

EBioMedicine. 2018 Mar;29:5-6. doi: 10.1016/j.ebiom.2018.02.021. Epub 2018 Feb 23.

DOI:10.1016/j.ebiom.2018.02.021
PMID:29496459
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5925610/
Abstract
摘要

相似文献

1
Mesenchymal Stem Cell-derived Neural Progenitor Cells in Progressive Multiple Sclerosis: Great Expectations.间充质干细胞来源的神经祖细胞在进展性多发性硬化症中的应用：寄予厚望。
EBioMedicine. 2018 Mar;29:5-6. doi: 10.1016/j.ebiom.2018.02.021. Epub 2018 Feb 23.
2
Induced Stem Cells as a Novel Multiple Sclerosis Therapy.诱导干细胞作为一种新型的多发性硬化症治疗方法。
Curr Stem Cell Res Ther. 2016;11(4):313-20. doi: 10.2174/1574888x10666150302110013.
3
The potentials of umbilical cord-derived mesenchymal stem cells in the treatment of multiple sclerosis.脐带间充质干细胞在多发性硬化症治疗中的潜力。
Rev Neurosci. 2019 Nov 26;30(8):857-868. doi: 10.1515/revneuro-2018-0057.
4
Phase I Trial of Intrathecal Mesenchymal Stem Cell-derived Neural Progenitors in Progressive Multiple Sclerosis.多发性硬化症进展期鞘内注射间充质干细胞源性神经前体细胞的Ⅰ期临床试验。
EBioMedicine. 2018 Mar;29:23-30. doi: 10.1016/j.ebiom.2018.02.002. Epub 2018 Feb 3.
5
Mesenchymal stem cells for multiple sclerosis: does neural differentiation really matter?间充质干细胞治疗多发性硬化症：神经分化真的重要吗？
Curr Stem Cell Res Ther. 2011 Mar;6(1):69-72. doi: 10.2174/157488811794480744.
6
Clinical and pathological effects of intrathecal injection of mesenchymal stem cell-derived neural progenitors in an experimental model of multiple sclerosis.鞘内注射间充质干细胞源性神经前体细胞对实验性多发性硬化模型的临床和病理影响。
J Neurol Sci. 2012 Feb 15;313(1-2):167-77. doi: 10.1016/j.jns.2011.08.036. Epub 2011 Oct 1.
7
Clinical safety of intrathecal administration of mesenchymal stromal cell-derived neural progenitors in multiple sclerosis.鞘内注射间充质基质细胞源性神经祖细胞治疗多发性硬化症的临床安全性。
Cytotherapy. 2016 Dec;18(12):1476-1482. doi: 10.1016/j.jcyt.2016.08.007. Epub 2016 Oct 7.
8
Stem cell therapy in multiple sclerosis: a future perspective.干细胞疗法治疗多发性硬化症：未来展望。
Neurodegener Dis Manag. 2015;5(3):167-70. doi: 10.2217/nmt.15.6.
9
An observational study of autologous bone marrow-derived stem cells transplantation in seven patients with nervous system diseases: a 2-year follow-up.自体骨髓源性干细胞移植治疗神经系统疾病 7 例的观察性研究：2 年随访。
Cell Biochem Biophys. 2014 May;69(1):179-87. doi: 10.1007/s12013-013-9756-8.
10
Neuralized mesenchymal stem cells (NMSC) exhibit phenotypical, and biological evidence of neuronal transdifferentiation and suppress EAE more effectively than unmodified MSC.神经化间充质干细胞 (NMSC) 表现出神经元转分化的表型和生物学证据，比未修饰的 MSC 更有效地抑制 EAE。
Immunol Lett. 2019 Aug;212:6-13. doi: 10.1016/j.imlet.2019.05.009. Epub 2019 May 30.

引用本文的文献

1
Advances in the Treatment of Multiple Sclerosis.多发性硬化症的治疗进展。
Neurol Clin. 2021 Feb;39(1):21-33. doi: 10.1016/j.ncl.2020.09.002. Epub 2020 Nov 7.
2
Safety and efficacy of stem cell therapy for treatment of neural damage in patients with multiple sclerosis.干细胞疗法治疗多发性硬化症患者神经损伤的安全性和有效性。
Stem Cell Investig. 2019 Dec 27;6:44. doi: 10.21037/sci.2019.10.06. eCollection 2019.
3
Therapeutic Advances and Challenges in the Treatment of Progressive Multiple Sclerosis.治疗进展性多发性硬化症的治疗方法及挑战。
Drugs. 2018 Oct;78(15):1549-1566. doi: 10.1007/s40265-018-0984-5.

本文引用的文献

1
Phase I Trial of Intrathecal Mesenchymal Stem Cell-derived Neural Progenitors in Progressive Multiple Sclerosis.多发性硬化症进展期鞘内注射间充质干细胞源性神经前体细胞的Ⅰ期临床试验。
EBioMedicine. 2018 Mar;29:23-30. doi: 10.1016/j.ebiom.2018.02.002. Epub 2018 Feb 3.
2
Cell-based therapeutic strategies for multiple sclerosis.用于治疗多发性硬化症的基于细胞的治疗策略。
Brain. 2017 Nov 1;140(11):2776-2796. doi: 10.1093/brain/awx154.
3
High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS.大剂量免疫抑制疗法和自体造血干细胞移植治疗复发缓解型多发性硬化症。
Neurology. 2017 Feb 28;88(9):842-852. doi: 10.1212/WNL.0000000000003660. Epub 2017 Feb 1.
4
The secretome of periodontal ligament stem cells from MS patients protects against EAE.多发性硬化症患者牙周韧带干细胞的分泌组可预防 EAE。
Sci Rep. 2016 Dec 7;6:38743. doi: 10.1038/srep38743.
5
Mesenchymal stem cell transplantation in multiple sclerosis.间充质干细胞移植治疗多发性硬化症
J Neurol Sci. 2013 Oct 15;333(1-2):43-9. doi: 10.1016/j.jns.2012.12.009. Epub 2013 Jan 4.
6
Characterization of autologous mesenchymal stem cell-derived neural progenitors as a feasible source of stem cells for central nervous system applications in multiple sclerosis.鉴定自体间充质干细胞源性神经前体细胞作为多发性硬化症中枢神经系统应用中干细胞的可行来源。
Stem Cells Transl Med. 2012 Jul;1(7):536-47. doi: 10.5966/sctm.2012-0015. Epub 2012 Jun 28.
7
Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-γ licensing.冷冻保存的间充质基质细胞由于热休克反应和干扰素γ许可受损，表现出免疫抑制功能受损。
Cytotherapy. 2012 Feb;14(2):147-52. doi: 10.3109/14653249.2011.623691. Epub 2011 Oct 27.
8
Clinical and pathological effects of intrathecal injection of mesenchymal stem cell-derived neural progenitors in an experimental model of multiple sclerosis.鞘内注射间充质干细胞源性神经前体细胞对实验性多发性硬化模型的临床和病理影响。
J Neurol Sci. 2012 Feb 15;313(1-2):167-77. doi: 10.1016/j.jns.2011.08.036. Epub 2011 Oct 1.
9
Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice.人骨髓基质细胞治疗可改善实验性自身免疫性脑脊髓炎（EAE）小鼠的神经功能恢复。
Exp Neurol. 2005 Sep;195(1):16-26. doi: 10.1016/j.expneurol.2005.03.018.
10
Adult stem cells for tissue repair - a new therapeutic concept?用于组织修复的成体干细胞——一种新的治疗理念？
N Engl J Med. 2003 Aug 7;349(6):570-82. doi: 10.1056/NEJMra022361.